×

Jounce Therapeutics to Deliver Keynote Address and Overview of Lead Program at PEGS Boston 2016

CAMBRIDGE, Mass., April 19, 2016 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient enrichment strategies, today announced that Deborah Law, D. Phil., chief scientific officer, will be featured as a keynote speaker at Cambridge Healthtech Institute’s 12th Annual Protein Engineering Summit (PEGS) Boston during the Plenary Keynote Session on Monday, April 25, 2016 at 4 p.m. ET. The conference is being held April 25-29, 2016 at the Seaport World Trade Center in Boston.

In addition to the keynote, Dr. Law will present an overview of Jounce’s lead inducible T cell co-stimulator (ICOS) program, JTX-2011. Details of the presentation are as follows:

Date & Time: April 29, 2016 at 9:05 a.m. ET
Session: Emerging Agonists and Antagonist Targets
Title: Preclinical Evaluation of JTX-2011, an Anti-ICOS Agonist Antibody

About Jounce Therapeutics
Jounce Therapeutics is an immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers, designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com

Source:Jounce Therapeutics, Inc.